Paul A. Grayson - 15 Nov 2024 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
Director
Signature
/s/ Kaitlyn Arsenault, as Attorney-in-Fact
Issuer symbol
SKYE
Transactions as of
15 Nov 2024
Net transactions value
-$432,061
Form type
4
Filing time
19 Nov 2024, 21:14:59 UTC
Previous filing
30 Oct 2024
Next filing
26 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SKYE Common Stock Sale $1,704 -307 -0.09% $5.55 345,945 15 Nov 2024 Direct F1
transaction SKYE Common Stock Sale $430,358 -86,244 -25% $4.99 259,701 18 Nov 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax obligations in connection with the vesting and settlement of performance-based restricted stock units.
F2 The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $4.98 to $5.08, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade.